UPDATE 3-Novartis beats forecasts with $6 billion profit as it navigates expiring patents

(Adds analyst comments throughout, adds shares in paragraph 2) * Entresto sales fall 50% as US generic competition intensifies * Novartis maintains full-year operating profit outlook * Shares rise 2%

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)